abiraterone vs octreotide
Side-by-side comparison of abiraterone and octreotide Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Zytiga
Sandostatin
Abiraterone (Zytiga) is a medicine used with prednisone to treat prostate cancer that has spread. It works by lowering the amount of androgen your body makes.
Octreotide is a drug that mimics a natural hormone in your body. It is used to treat certain conditions caused by too much of certain hormones.
Abiraterone is used to treat prostate cancer that has spread to other parts of the body. It is for cancers that are castration-resistant, meaning they no longer respond to hormone therapy alone. It is also used for high-risk castration-sensitive prostate cancer. You will take this medicine with prednisone.
Octreotide is used to lower growth hormone and insulin-like growth factor-1 in people with acromegaly who haven't responded to other treatments. It also helps manage severe diarrhea and flushing caused by carcinoid tumors. Additionally, it can treat watery diarrhea caused by VIPomas (tumors that release vasoactive intestinal peptide).
Abiraterone blocks an enzyme called CYP17, which your body needs to make androgens. Androgens can help prostate cancer grow. By blocking this enzyme, abiraterone lowers androgen levels and slows cancer growth.
This medicine works by mimicking somatostatin, a natural hormone in your body. It reduces the amount of certain hormones, like growth hormone, that your body makes. By doing this, it helps control the symptoms caused by having too much of these hormones.
- • Feeling tired
- • Joint pain
- • High blood pressure
- • Feeling sick to your stomach
- • Swelling
- • Gallbladder problems
- • Slow heart rate
- • Diarrhea
- • Loose stools
- • Nausea
- Death 1,390
- Feeling tired 1,022
- Hot flash 678
- Weakness 562
- Worsening of disease 561
- The medicine is not working 658
- Using the medicine for a condition it is not approved for 627
- Diarrhea 526
- Death 375
- Nausea 345
Abiraterone can cause problems with mineralocorticoid excess, like high blood pressure, low potassium, and fluid retention. If you have heart problems, your doctor will monitor you closely. This medicine can also cause liver problems, which can be severe. Your doctor will check your liver function regularly. Do not take abiraterone with radium Ra 223 dichloride. Abiraterone can harm an unborn baby, so men should use effective birth control if their partner can get pregnant.
Octreotide can cause heart problems, including a higher risk of certain types of heart block. Your doctor may monitor your heart if you receive this drug intravenously. It can also cause gallbladder problems, high or low blood sugar, and thyroid issues. Tell your doctor right away if you notice new or worsening symptoms.
Abiraterone can cause harm to an unborn baby. Men who are taking abiraterone should use effective birth control during treatment and for 3 weeks after the last dose if their partner is able to get pregnant. It is not known if abiraterone passes into breast milk.
There is limited information about the safety of octreotide during pregnancy. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if octreotide passes into breast milk, so talk to your doctor about breastfeeding while using this medicine.
How to Read This abiraterone vs octreotide Comparison
abiraterone is classified in the CYP17 Inhibitor drug class, while octreotide sits within the Somatostatin Analog class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, abiraterone has 4,213 submissions while octreotide has 2,531. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between abiraterone and octreotide — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.